Adoptive immunotherapy with tumor-infilirating lymphocytes (TILS) causes regression of some human tumors. However, the sustained proliferation and antitumor activity of TILS requires the coadministration of potentially toxic amounts of interleukin-2 (IL-2). In an effort to overcome the requirement by T cells for 11-2, we have introduced atternative growth factor receptors that use the relatively nontoxic cytokine erythropoietin (Epo) as a ligand. In our model system, the coexpression of chimeric receptors consisting of the extracellular portion of the Epo receptor (EpoR) and the UMOR-INFILTRATING lymphocytes (TJLs) are derived from solid tumors by culturing single cell suspensions of tumor in vitro in recombinant human interleukin-2 (IL-2).' The adoptive transfer of TILs plus the systemic administration of IL-2 can mediate tumor regression in selected patients with advanced cancer.2z3 A major limitation to the successful application of this treatment results from toxicity associated with IL-2 administration, which is required to stimulate the proliferation and antitumor activity of the adoptively transferred lympho~ytes?~.~ We are studying ways to genetically modify TILS to alter their dependence on L 2 and substitute it with reactivity to a molecule that can be systemically administrated with little toxicity.
UMOR-INFILTRATING lymphocytes (TJLs) are derived from solid tumors by culturing single cell suspensions of tumor in vitro in recombinant human interleukin-2 (IL-2).' The adoptive transfer of TILs plus the systemic administration of IL-2 can mediate tumor regression in selected patients with advanced cancer.2z3 A major limitation to the successful application of this treatment results from toxicity associated with IL-2 administration, which is required to stimulate the proliferation and antitumor activity of the adoptively transferred lympho~ytes?~.~ We are studying ways to genetically modify TILS to alter their dependence on L 2 and substitute it with reactivity to a molecule that can be systemically administrated with little toxicity.
Recombinant human erythropoietin (Epo) has been wellcharacterized and is tolerated with minimal toxicity when administrated in vivo."1o Chemical cross-linking studies suggest that the Epo receptor (EpoR) exists as a multimeric complex with other membrane proteins"*'* that are actively involved in the transduction of the Epo signal through interaction with the extracellular region of EpoR.I3-l5 In spite of these findings, a point mutation (kg129 + Cys) in the extracellular region of the mouse EpoR has been reported to form disulfide-linked oligomers without ligand binding and results in the constitutive action of the EpoR. This suggests that the ligand-induced dimerization of wild-type EpoR itself is crucial for triggering the Epo signa1.I6.'' Similarly, dimerization of the p and y subunits of the L 2 receptor (IL-2R) may be essential for triggering the E -2 signal. Therefore, the formation of chimeric molecules using the EpoR and the IL-2R subunits might allow triggering of the IL-2R using Epo as a ligand.
In this study, we attempted to confer the ability to respond to Epo on a mouse E-2-dependent T-cell line, CTL-D,'8~'9 as a model for human TILs, by introducing recombinant retroviruses expressing either human EpoR or human EpoR-IL-2R subunit chimeric receptors. Our studies showed that coexpression of the chimeric EpoR/IL-2R, but not the wildtype EpoR, in T cells could provide dependence on an alternative cytokine, Epo.
T

MATERIALS AND METHODS
Cell culture. CTL-D cell (from Dr Z. Eshhar, Weizmann Institute, Rehovot, Israel), an IL-2-dependent murine T-cell line, was maintained in RPMI 1640 medium supplemented with 10% (vel/ VOl) bovine calf serum and 50 U/mL of recombinant human IL-2 Retroviral vector construction. The pYM vector used for receptor gene expression was initially constructed with the IL-2Ra. pYM/ IL-2Ra was constructed by replacing the cytomegalovirus promotor of pLNCXZo with human elongation factor a @Fa) enhancer-like and promotor regions and IL-2Ra cDNA. Briefly, pLXSNm-2Ra was constructed by inserting a 0.9-bp blunt-ended Xba I fragment encoding human L 2 R a from the plasmid CDM8/Tac2' into the Hpa I site of pLXSN.2' A 0.9-kb cDNA fragment for L-2Ra was excised from pLXSNIIL-2Ra by EcoRI and Xho I digestion in which the Xho I site was blunt-ended. A 0.4-kb EFa enhancer-like fragment was excised using Bgl I1 and Xho I from pEFP?* A 0.5-kb EFa promotor fragment was obtained by the polymerase chain reaction using the oligonucleotides, 5"ITGGAGCTCGAGCAGCAATGG-cine, Baltimore, MD) into the BamHI site of pYM using BamHI linkers. The chimeric EpoIUIL-2R subunit receptor constructs were made as follows. DNA fragments encoding the transmembrane and intracellular region of IL-2RP or IL-2Ry and the extracellular region of EpoR were isolated from pEFP, pIL-2Ry2," and pYMEpoR, respectively, and were subcloned into pUC19 (pUCIL-2RPint, pUCIL-2Ryint, and pUCEpoRext), and the extracellular region of EpoR was connected with the transmembrane and intracellular region of IL-2RP or IL-2Ry and inserted into the BamHI site of pYM. More precisely, cDNA for the transmembrane and intracellular region of IL-2RD was isolated in two fragments, a 163-bp Eae IAut I1 fragment and an 801-bp Aar 11-BnmHI fragment from pEFP. The BamHI site was located in the 3' end of the IL-2RP cDNA insert and was derived from pSP64 linker sequence, and these two fragments were then inserted into the Kpn I-Bum HI sites of pUCI9 (pUCIL-2RPint) using pCGATATCA'M'CCGTGGCTC and pGG-CCGAGCCACGGAATGATATCGGTA, which create an EcoRV site at 5' boundary of the transmembrane region. To isolate a fragment coding the transmembrane and intracellular region of IL-2Ry, the IL-2Ry fragment was first cut out of pIL-2Ry2 with Xba 1 and Bsp MI, and a BamHI linker was attached, and again this fragment was digested with BamHI and Xmn I. The resultant 430-bp Xmn IBamHI fragment was inserted into the Kpn I-BarnHI sites of pUC 19 (pUCIL-2Ryint) using the adaptors pCGATATCC and pGGATA-TCGGTAC, which create an EcoRV site at the S' boundary of the transmembrane region of IL-2Ry. EpoR fragments encoding the extracellular region of EpoR (a 252-bp BamHI-Xho I fragment and a 497-bp Xho I-Ava I1 fragment) were isolated from pYM/EpoR and ligated into the Kpn I-BamHI sites of pUC19 (pUCEpoRext) using pGACCCCCAGCTGGGTAC and pCCAGCTGGGG, which create a Pvu I1 site at the 3' boundary of the extracellular region of EpoR. The chimeric receptors were then constructed by insertion of an Xba I-Pvu I1 fragment from pUCEpoRext and an EcoRV-BamHI fragment from pUCIL-2RPint or pUCIL-2Ryint into the BamHIXbu I sites of pUC19 (pUCEPR or pUCEyR). Finally, pYMEPR and pYMEyR were constructed by inserting BamHI fragments from pUCEPR or pUCEyR into the BamHI site of pYM, respectively (pYMEPR, pYMEyR).
Production of rerroviral producer line. The retroviral vectors were transinfected into PA317" in the presence of 8 pg/mL of polybrene (Aldrich, Milwaukee, WI) using virus transiently expressed in an ecotropic packaging line GP + E86" that was transfected with the corresponding plasmid vector by calcium-phosphate method. The transinfected PA317 cells were selected in 400 pg/mL of Geneticin (Life Technologies, Gaithersburg, MD), and the amphotropic virus producer clones were chosen on the basis of high virus titer. To get the ecotropic virus producer lines, GP+E86 ecotropic retrovirus packaging cells were incubated with amphotropic virus-containing cell-free supernatant derived from the abovementioned PA317 virus producer clone in the presence of 8 pg/mL of polybrene and were selected in I mg/mL of Geneticin. Retrovirus supernatants used in this study had a virus titer ranging from I X I O 5 to I X 10' colony-forming units per milliliter when assayed for their ability to confer neomycin resistance on NIH3T3 cells.
Infection of recombinant viruses into CTL-D cells. CTL-D cells were usually maintained in the RPMI 164O/lL-2 medium (10% fetal calf serum, 50 U/mL of rIL-2). The amphotropic or ecotropic viruscontaining cell-free supernatant was used for the first or second infection into CTL-D cells, respectively.
First, CTL-D cells were incubated in the first viral supernatant supplemented with 4 pg/mL of polybrene and I O 0 U/mL of rIL-2. After 24 hours, cells were washed once, and fresh RPMI1640/IL-2 medium was added. G418 selection was initiated 2 days after virus infection using 800 p g / d of Geneticin. For the second infection of the first infected CTL-D cells. the (3418-resistant cells were reinfected by incubating at 1 X IO' cells in 10 mL of RPMI1640/IL-2 medium and then adding I O mL of the second viral supernatant containing 8 pg/mL o f polybrene and 50 U/mL oflL-2. The next day, the culture medium was changed to fresh RPM11 640fiL-2 medium. On day 3. the cells were washed 3 times to remove IL-2 and then cultured in RPMI 1640 medium containing no ligand or 5 U/mL of recombinant human Epo (Amgen, Thousand Oaks, CA) or 50 U/mL of recombinant human IL-2.
Southern blot. Southern blot analyses with 5 pg per lane of BanzHI-digested genomic DNA were performed as described previously."
ftnmunoprecipirarion. Immunoprecipitation of EpoR and chimeric receptors was performed as described previously, using antihuman EpoR monoclonal antibody, 16.5.1 (kindly provided by Genetics Institute, Andover, MA)."
Western blot ana1y.vi.s with antiphosphotyrosine antibodie.\. I mmunoblot analysis was performed as described previously," with some modifications. A total o f 1 X 10' cells were deprived of cytokines for 6 hours, and, during the last 30 minutes, the medium was supplemented with 50 mmoVL sodium orthovanadate (Sigma, St Louis, MO). Cells were then stimulated with 500 U/mL of IL-2 or 50 U/mL of Epo for 10 minutes. Lysates (30 /*L) were electrophoresed on sodium dodecyl sulfate-7.SLTc polyacrylamide gel and transferred to nitrocellulose membrane (Amersham, Arlington
Heights. IL). After blocking of the blotted filter, each filter was incubated overnight at 4°C with an antiphosphotyrosine antibody (4GI0 [UBI, Lake Placid, NY] or PY20 [ICN, Costa Mesa, CA], respectively) at I pg/mL in TBS-T containing 5% bovine serum albumin. The filter was then washed 6 times with TBS-T, and immune complexes were then visualized with enhanced chemiluminescence detection reagents (Amersham).
RESULTS
A retroviral vector, pYM. To constitutively express the receptor genes in T cells, we constructed a new retroviral vector pYM using the upstream region of human EFa gene as a promotor (Fig l) .22,29,3" The ability of EFa promotor to express an inserted gene in T cells was shown using human IL-2Ra cDNA as a reporter gene and was detected by anti-IL-2Ra immunostaining. Expression was compared with that from a pLXSN construct:' which is broadly used in studies of gene therapy. The fluorescence-activated cell sorter (FACS; Becton Dickinson, Mountain View, CA) profiles showed that the expression of IL-2Ra gene was greater in the cells infected with virus from pYM construct as compared with those from pLXSN construct in CTL-D cells (data not shown).
Expression of EpoR in IL-2-dependent T cells. We initially evaluated if expression of EpoR in T cells would confer Epo dependence. Although several groups reported that EpoR was not functional in IL-2-dependent murine CTLL-2 cell one group showed that an IL-2-dependent CTLL-2 expressing EpoR by gene transfer responded to Epo." First, we constructed a pYM/EpoR and showed that it could direct the expression of functional EpoR by converting transduced mouse IL-3-dependent 32D cells34 to Epo dependence (data not shown).2' Subsequently, the EpoR virus was used to infect CTL-D cells [termed CTL-D(EpoR)], and the cells were analyzed for expression of EpoR by FACS (Fig  2a) using the antihuman EpoR monoclonal antibody, 16.5.
The responsiveness to Epo was measured by ['HIthymidine uptake (see Fig 4) . Relative fluorescence intensity 
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CTL-D(EpoR) cells. In addition, CTL-D(EpoR) cells were cultured with 5 U/mL of Epo for at least 4 weeks, but all cells died. Thus, it appeared that CTL-D cells lacked molecule(s)
involved in the Epo-signaling pathway, and, thus, pYM/ EpoR virus would not be useful for our purpose.
Sequential infection of virus expressing EPR or EyR and Epo selection and growth projile of the CTL-D infectants.
Next, we attempted to use the IL-2 signaling pathway to confer Epo dependency on CTL-D cells, because CTL-D cells and TILS are IL-2-dependent and the machinery necessary for IL-2 signaling should be intact. The IL-2R complex is composed of three subunits, a, p, and y . IL-2Ra is only essential for the formation of high-affinity receptor but is not involved in IL-2 signaling. IL-2RP or IL-2Ry alone can not bind IL-2,24.35.36 but coexpression of both subunits forms a functional intermediate affinity IL-2R.24 The heterodimerization of IL-2RP and IL-2Ry appears to be essential for IL-2 binding and IL-2-induced signal transduction. Because EpoR dimerization probably occurs on binding of the ligand, we speculated that chimeric receptors bearing EpoR on the outside and either IL-2P or IL-2Ry on the inside might dimerize in the presence of Epo to trigger an IL-2 signal. Therefore, two chimeric receptors (EPR or EyR) were constructed using the extracellular region of human EpoR and the transmembrane and intracellular region of human IL-2RP or IL-2Ry. Genes encoding these chimeric receptors were inserted into pYM (Fig l) , and the virus-producer lines were obtained. First, we infected CTL-D cells with each of the amphotropic EDR and EyR viruses [termed CTL-D(EPR) and CTL-D(EyR)] and analyzed the expression of chimeric receptors (Fig 2b) . The expression of EPR was observed at marginally detectable levels. The low expression of EPR was also observed in two independent EPR-virusinfected PG13 cell clones (ATCC CRL 10686; American Type Culture Collection, Rockville, MD; data not shown). Neither of these transduced CTL-D cells responded to Epo (data not shown). The low expression of EPR seemed to be related to the nature of the protein, because the levels of mRNA were almost the same when compared with those for EpoR or EyR (data not shown). Next, we infected the second virus into each of CTL-D (EPR) and CTL-D (EyR) and maintained them in the presence or absence of 5 U/mL of Epo or 50 U/mL of IL-2 (Fig 3) . After selection in Epo, the only proliferating CTL-D cells were those resulting from sequential infection of both EPR virus and EyR virus, although the appearance rate of the Epo-dependent cells was much slower than that of G418-resistant cells from the parental CTL-D cells infected with the same virus supernatant. The other single virus-infected CTL-D cells died in Epo selection medium (Fig 3) . This experiment was repeated twice, and the same results were obtained. Furthermore, we repeatedly tried to obtain Epo-dependent cells from CTL-D cells infected with either EPR or EyR virus alone. Even when cells were transduced by cocultivation with the corresponding virus-producer cells, all attempts failed. The infection with both EPR and EyR viruses was required to induce Epo dependency. In addition, the expression of the chimeric receptors were greatly enhanced by Epo selection (Fig 2b) when examined by FACS analysis. It is probable that the cells expressing higher levels of chimeric receptors would be selected in Epo selection medium preferentially.
To further analyze the response to Epo, the proliferative response of cells in varying concentrations of Epo or IL-2 was examined using ['HI-thymidine uptake (Fig 4) . There was a clear dose-dependent response to Epo by Epo-selected CTL-D cells. Additionally, these cells showed long-term growth in response to Epo (data not shown). Thus, it appeared that the level of protein coded for by the first virus may have been preferentially expressed.
Southern blot analysis
DISCUSSION
A major problem in immunotherapy is the toxicity associated with the administration of IL-2, and we have been seeking less toxic alternatives to IL-2 for sustaining the growth of TILS in vivo. In this study, we have conferred Epo dependence on the IL-2-dependent murine T-cell line, CTL-D, by expressing chimeric EpoML-2R subunits using retroviral vectors.
Previous studies using epidermal growth factor receptor (EGFR)/EpoR or kit/EpoR chimeric receptors in mouse IL- In the current study, we used the interaction of intracellular regions of IL-2RP and IL-2Ry that has been reported to cause a mitogenic signal in CTLL-2 cells after heterodimeriati ion.^^.^' Our data showed that coexpression of EPR and EyR chimeric receptors resulted in Epo-dependent growth of CTL-D cells. In addition, wild-type EpoR was not functional, further suggesting that the mitogenic signal by Epo in CTL-D(EPR, EyR, Epo-selected) and CTL-D(EyR, EPR, Epo-selected) was induced by the interaction of intracellular regions of IL-2RP and IL-2Ry but not by the interaction of extracellular region of EpoR and the putative additional molecules. Thus, although we did not directly show the dimerization of the chimeric receptors containing the extracellular portion of EpoR, our data further support the concept that EpoR binding of the ligand results in the formation of EpoR homodimers. In addition, in studying the signaling, we have looked at the tyrosine phosphorylation of proteins after stimulation through the chimeric receptor proteins. Although preliminary, the studies have suggested that the Epoinduced signal via both EPR and EyR is similar to that induced by IL-2 (data not shown). Further study will be required to show the direct association of EpoRs after Epo binding and to further elucidate the signaling pathways involved in mitogenesis.
A major problem in immunotherapy is the toxicity associated with the administration of IL-2, which may interrupt treatment. Epo is a potential alternative ligand, because recombinant human Epo has been safely used for the therapy of anemia on a clinical basis. Our initial attempt to confer Epo dependency on CTL-D cells by introducing wild-type EpoR failed. However, by making chimeric receptors consisting of the extracellular region of EpoR and the intracellular region of IL-2R subunits, we succeeded in making Epodependent CTL-D cells. Furthermore, the mitogenic signaling by Epo appeared to be caused by the activation of IL-2 -E -E signaling machinery after Epo binding. Thus, this study offers the possibility that immunotherapy could be made safer and more effective by allowing the administration of Epo, rather than the more toxic cytokine IL-2, to sustain the in vivo proliferation and antitumor activity of transferred TILS.
